Browsing by Yonsei Author : Cho, Byoung Chul

Name:
조병철 [Cho, Byoung Chul]
Department :
College of Medicine - Dept. of Internal Medicine
Y-HRN :
(Yonsei Health Research Network)

Results 1-50 of 146.

This table browses all dspace content
Issue DateTitleYonsei Author(s)
2018Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck고윤우, 김진아, 김혜련, 윤선옥, 조병철, 최은창, 홍민희
2018A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer금기창, 김다희, 김세헌, 김혜련, 조남훈, 조병철
2018Characteristics and Outcome of ROS1-Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice 김혜련, 안병철, 조병철, 홍민희
2018Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions조병철
2018Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. 조병철
2018Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.김혜련, 심효섭, 조병철, 표경호, 홍민희
2018Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.김혜련, 안병철, 조병철, 홍민희
2018Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation김대준, 김진아, 김혜련, 박성용, 백순명, 심효섭, 윤미란, 이진구, 이한나, 조병철, 표경호, 홍민희
2017Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective 김대준, 이익재, 이창걸, 장지석, 조병철, 차지혜
2017Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma김은경, 김혜련, 윤선옥, 조병철, 허수진
2017Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.김주항, 김혜련, 심효섭, 임선민, 조병철
2017Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042)조병철
2017Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer조병철
2017Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study 김혜련, 서창옥, 이창걸, 장종희, 조병철
2017Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer김혜련, 심효섭, 조병철, 차윤진
2017A randomized; phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (vol 8; pg 15943; 2017) 김주항, 김혜련, 정인경, 조병철
2017Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma금기창, 김세헌, 김혜련, 박영민, 조남훈, 조병철
2017Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers조병철
2017Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization 김혜련, 심효섭, 이진구, 이창영, 정인경, 조병철, 차윤진, 홍민희
2017Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition김은경, 김한상, 신상준, 정기양, 정민규, 조병철
2017Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs김상우, 김성무, 김혜련, 이충근, 조병철
2017Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer강한나, 김상균, 김성무, 김혜련, 김환, 윤미란, 임선민, 조병철, 표경호
2017Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy 김현주, 신성관, 이상길, 이용찬, 이창걸, 조병철
2017Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer조병철
2017Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study김혜련, 조병철
2017Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis 김지형, 김혜련, 박형순, 심효섭, 이진구, 이창영, 조병철, 차윤진, 허수진, 홍민희
2017Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?조병철
2017Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma김은영, 김진아, 김혜련, 백순명, 심효섭, 이진구, 조병철, 홍민희
2017Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer김혜련, 박용구, 장원석, 장진우, 정현호, 조병철
2017Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer김혜련, 조병철
2017ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)조병철
2017Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma 박영년, 유정은, 임선민, 조병철
2016Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck 고윤우, 김상우, 김한상, 김혜련, 조병철, 최은창
2016Alteration status and prognostic value of MET in head and neck squamous cell carcinoma 김혜련, 윤선옥, 조병철, 조윤아, 허수진
2016Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.김혜련, 심효섭, 이창영, 조병철, 차윤진
2016PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. 김대준, 김현기, 김혜련, 김효송, 박준철, 배윤성, 신성관, 이상길, 이용찬, 이창걸, 정현수, 조병철, 허진
2016Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium) 김혜련, 임선민, 조병철
2016ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models김혜련, 박혜지, 임선민, 조병철, 표경호, 한주연
2016Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma고윤우, 김주항, 김혜련, 이창걸, 조병철, 최은창
2016PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients 고윤우, 김은경, 김혜련, 윤선옥, 정인경, 조병철, 최은창, 표경호, 허수진, 홍민희
2016Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy김주항, 김혜련, 박형순, 이민구, 조병철, 조응혁
2016Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma: Early Response and Dosimetric Evaluation.김준원, 김혜련, 서양권, 이창걸, 조병철, 조재호, 최치환
2016The Clinical Usefulness of (18)F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma금기창, 윤미진, 윤홍인, 이정심, 이창걸, 조병철
2016Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus 김상우, 김소라, 김현기, 김혜련, 김효송, 박형순, 이민구, 임선민, 정현철, 조병철
2016Clinical course of stage IV invasive mucinous adenocarcinoma of the lung김혜련, 심효섭, 이혜정, 조병철
2016A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)심효섭, 임선민, 정민규, 조병철, 최종락
2016Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy 김혜련, 백순명, 조병철, 표경호
2016EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines 김민환, 김주항, 김혜련, 문용화, 백순명, 임선민, 조병철
2016Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer조병철
2016Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial조병철

Browse